Hp. Hammes et al., SECONDARY INTERVENTION WITH AMINOGUANIDINE RETARDS THE PROGRESSION OFDIABETIC-RETINOPATHY IN THE RAT MODEL, Diabetologia, 38(6), 1995, pp. 656-660
Citations number
21
Categorie Soggetti
Endocrynology & Metabolism","Medicine, General & Internal
Primary prevention with aminoguanidine an inhibitor of advanced glycat
ion end product (AGE) formation - has been successfully employed to pr
event diabetic retinopathy in the rat. However, it is unknown whether
inhibition of AGE formation is still effective in a secondary interven
tion strategy. The present study addresses this question by comparing
secondary intervention with aminoguanidine with syngeneic islet transp
lantation in the rat model. After 6 months of diabetes, one group was
treated with aminoguanidine (50 mg/100 ml drinking water; D-AG) while
another group received syngeneic transplantation of collagenase-ficoll
isolated islets by intraportal injection (Tx). After an additional 4
months, both groups were compared to a normal (NC 10) and diabetic (DC
10) control group. Retinal autofluorescence was increased 2.5-fold af
ter 6 months and increased 3.7-fold after 10 months of diabetes (p < 0
.001). Aminoguanidine and islet Tx retarded the further accumulation o
f autofluorescence equally (p < 0.001 vs DC 10), although the values w
ere higher than those observed in DC at 6 months (p < 0.001). Diabetes
was associated with a 2.7-fold increase in acellular capillaries afte
r 6 months and a 4.1-fold increase after 10 months. Treatment with ami
noguanidine or islet Tx reduced but did not completely attenuate the p
rogression of vascular occlusion (p < 0.001 vs DC 10; D-AG vs DC 6, p
< 0.05; Tx vs DC 6, p < 0.01), Both treatments reduced endothelial pro
liferation (22.4% after 10 months; p < 0.001) and completely arrested
pericyte dropout (40% after 10 months; p < 0.001). These data demonstr
ate that aminoguanidine is as effective as islet transplantation in re
tarding the progression of diabetic retinopathy in a secondary prevent
ion setting.